timing of high|efficacy disease modifying therapies for relapsing ...

timing of high-efficacy disease modifying therapies for relapsing ...

Conclusions Early commencement of high-efficacy DMTs in relapsing-remitting multiple sclerosis provides superior control over relapse activity than their ...

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis

The literature suggests that treatment with high-efficacy immunotherapies is more potent in suppressing relapse activity when initiated early vs. with a delay ...

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis

The evidence reported for disability and MRI outcomes is inconclusive. Keywords: Alemtuzumab; Disease modifying therapy; Fingolimod; Natalizumab; Relapsing- ...

Timing of high-efficacy therapy for multiple sclerosis - The Lancet

High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies.

Early use of high-efficacy disease‑modifying therapies makes the ...

Recent growing pieces of evidence are suggesting that early initiation of HE-DMTs may have a beneficial long-term impact on disease progression in MS patients [ ...

Initial high-efficacy disease-modifying therapy in multiple sclerosis

In the secondary outcome of time to first relapse, the absolute probabilities of an event at 2 and 4 years of follow-up were 51.8% (95% CI 43.8%–59.8%) and 66.9 ...

Timing of high-efficacy therapy for multiple sclerosis: a retrospective ...

High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies.

Multiple sclerosis: time for early treatment with high-efficacy drugs

Patients initiating their treatment with HETA, regardless of prognostic factors and MRI burden at baseline, showed significantly lower ...

Sequencing of high-efficacy disease-modifying therapies in multiple ...

Treatment is most often initiated with first-line therapies followed by second-line high-efficacy DMTs in patients who continue to experience on-treatment ...

Escalating to medium‐ versus high‐efficacy disease modifying ...

In patients with relapsing remitting multiple sclerosis (RRMS) on low-efficacy disease modifying therapies (DMT), the optimal strategy on ...

Disease-Modifying Treatments and Time to Loss of Ambulatory ...

Although several disease-modifying treatments (DMTs) are available for the treatment of relapsing-remitting MS, in the PPMS phenotype, with the ...

Initial disease-modifying therapy for relapsing-remitting multiple ...

Outline ; DMT INDICATIONS, TIMING, AND GOALS · Who should be treated? ; CATEGORIES OF DMT · Monoclonal antibodies · Oral therapies ; FACTORS ...

High-Efficacy Therapies for Treatment-Naïve Individuals with ...

Historically, an escalation approach to DMT was used for newly diagnosed patients with RRMS. However, the evidence for clinical benefits of ...

Long-term clinical outcomes in patients with multiple sclerosis who ...

Natalizumab (TYSABRI®) is a high-efficacy DMT approved for the treatment of relapsing forms of MS on the basis of randomized clinical trials and ...

timing of high-efficacy disease modifying therapies for relapsing ...

The patients treated early with high-efficacy DMTs experienced less relapses (annualised relapse rate 0.22 versus 0.42) and were more likely to recover from ...

Quantifying the administration and monitoring time burden of several ...

... high-efficacy disease-modifying therapies (DMTs) with varied administration and monitoring requirements. Coupled with greater focus on ...

Use of Disease-Modifying Therapies in Pediatric Relapsing ...

Children on newer DMTs showed longer time to relapse, time to switch treatment, and time to new radiologic activity than patients on injectables ...

Evolution of Disease Modifying Therapy Benefits and Risks - Frontiers

For these reasons, the benefit of high efficacy DMT is front-loaded. Due to decreasing DMT efficacy and increasing risks, as patients approach 40–55 years, de- ...

Effectiveness of multiple disease-modifying therapies in relapsing ...

Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), ...

Multiple Sclerosis Therapy Consensus Group (MSTCG)

Data from observational studies suggest that initial treatment with a high-efficacy DMT may be associated with a lower risk of conversion to ...